As recently announced by Ascenion’s portfolio company Protectimmun, the three parties have agreed that Janssen will financially support preclinical studies of Protectimmun’s lead candidate for the prevention of allergic asthma. The studies will be conducted at Imperial College, London – one of Protectimmun’s academic partners.
Protectimmun’s approach is based on the observation that individuals who grew up in a farm environment are less likely to develop allergies than city dwellers. Together with its academic partners, the company has identified natural substances in farming environments that protect against the development of allergies and have selectively transferred them into innovative pharmaceutical combinations. The aim is to provide long-term and stable protection from hay fever and allergic asthma.
Further information:
Press release from Protectimmun